desmopressin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
vasopressin analogues 817 16679-58-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • desmopressin acetate hydrate
  • minirinmelt
  • desmopressin
  • adiuretin
  • minirin
  • desmopressin acetate
  • DDAVP
A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.
  • Molecular weight: 1069.22
  • Formula: C46H64N14O12S2
  • CLOGP: -2.31
  • LIPINSKI: 3
  • HAC: 26
  • HDO: 14
  • TPSA: 435.41
  • ALOGS: -3.99
  • ROTB: 19
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
25 mcg N
0.40 mg O
4 mcg P
0.24 mg SL

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 47 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0.12 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.40 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.10 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.242 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
June 18, 2019 PMDA FERRING PHARMACEUTICALS CO., LTD.
Feb. 21, 1978 FDA FERRING PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 753.31 17.75 310 6886 133228 90488023
Hyponatraemic encephalopathy 176.54 17.75 29 7167 277 90620974
Hypernatraemia 136.31 17.75 44 7152 9343 90611908
Craniopharyngioma 119.35 17.75 19 7177 146 90621105
Seizure 117.38 17.75 97 7099 152532 90468719
Hyponatraemic seizure 110.34 17.75 21 7175 489 90620762
Water intoxication 107.26 17.75 21 7175 570 90620681
Recalled product administered 100.52 17.75 21 7175 794 90620457
Cerebral salt-wasting syndrome 85.57 17.75 15 7181 217 90621034
Diabetes insipidus 85.36 17.75 24 7172 3188 90618063
Blood sodium decreased 75.55 17.75 39 7157 27574 90593677
Poor quality product administered 67.33 17.75 21 7175 3987 90617264
Pharyngeal haemorrhage 58.82 17.75 13 7183 643 90620608
Adrenocortical insufficiency acute 58.21 17.75 17 7179 2584 90618667
Renal salt-wasting syndrome 57.61 17.75 12 7184 447 90620804
Polyuria 51.82 17.75 22 7174 10018 90611233
Tonsillar disorder 50.99 17.75 13 7183 1189 90620062
Brain injury 50.30 17.75 20 7176 7718 90613533
Patent ductus arteriosus 48.78 17.75 17 7179 4552 90616699
Lethargy 46.10 17.75 39 7157 63100 90558151
Somnolence 44.67 17.75 68 7128 209016 90412235
Electrolyte imbalance 44.15 17.75 26 7170 23719 90597532
Premature baby 42.84 17.75 26 7170 25051 90596200
Urine output increased 41.57 17.75 12 7184 1750 90619501
Product prescribing error 40.86 17.75 27 7169 30118 90591133
Brain oedema 40.32 17.75 22 7174 17363 90603888
Drug interaction 39.30 17.75 75 7121 276378 90344873
Osmotic demyelination syndrome 37.92 17.75 10 7186 1044 90620207
Oesophageal disorder 36.47 17.75 12 7184 2701 90618550
Puncture site haematoma 35.83 17.75 6 7190 65 90621186
Labelled drug-disease interaction medication error 35.27 17.75 7 7189 204 90621047
Blood sodium increased 34.59 17.75 12 7184 3170 90618081
Hypopituitarism 32.89 17.75 10 7186 1743 90619508
Cutaneous lupus erythematosus 30.99 17.75 11 7185 3107 90618144
Puncture site haemorrhage 30.84 17.75 7 7189 391 90620860
Foetal exposure during pregnancy 30.25 17.75 26 7170 42949 90578302
Exposure during pregnancy 29.43 17.75 61 7135 238349 90382902
Hallucination 29.41 17.75 31 7165 65928 90555323
Nephrogenic diabetes insipidus 29.23 17.75 8 7188 962 90620289
Hepatitis toxic 29.08 17.75 11 7185 3714 90617537
Haemorrhagic disorder 28.89 17.75 8 7188 1004 90620247
Hypoosmolar state 28.71 17.75 6 7190 227 90621024
Mood altered 27.30 17.75 17 7179 17127 90604124
Acromegaly 27.04 17.75 5 7191 99 90621152
Joint swelling 26.85 17.75 4 7192 503296 90117955
Gastrointestinal infection 25.74 17.75 14 7182 10976 90610275
Blood sodium abnormal 25.65 17.75 7 7189 832 90620419
Scleroderma-like reaction 25.31 17.75 5 7191 142 90621109
Oligohydramnios 25.11 17.75 12 7184 7189 90614062
Thoracotomy 24.98 17.75 4 7192 32 90621219
Headache 24.71 17.75 134 7062 862612 89758639
Generalised tonic-clonic seizure 24.32 17.75 21 7175 34882 90586369
Urine output decreased 23.95 17.75 14 7182 12589 90608662
Neoplasm recurrence 23.21 17.75 9 7187 3250 90618001
Pituitary tumour benign 23.02 17.75 8 7188 2124 90619127
Premature delivery 22.43 17.75 21 7175 38741 90582510
Abortion induced 22.05 17.75 13 7183 11875 90609376
Diabetes with hyperosmolarity 22.03 17.75 3 7193 6 90621245
Germ cell cancer 21.94 17.75 4 7192 73 90621178
Multiple-drug resistance 21.31 17.75 11 7185 7765 90613486
Encephalopathy 21.00 17.75 22 7174 46422 90574829
Drug intolerance 20.80 17.75 5 7191 447586 90173665
Urine sodium increased 20.67 17.75 4 7192 102 90621149
Thirst 20.65 17.75 14 7182 16281 90604970
Insulin-like growth factor increased 20.19 17.75 6 7190 968 90620283
Insulin-like growth factor decreased 20.18 17.75 5 7191 407 90620844
Hypophagia 19.89 17.75 19 7177 35918 90585333
Hepatic enzyme increased 18.92 17.75 3 7193 360733 90260518
Nasal discomfort 18.60 17.75 9 7187 5539 90615712
Epistaxis 18.59 17.75 28 7168 85097 90536154
Glucose tolerance impaired 18.22 17.75 10 7186 7975 90613276
Hypoglycaemia 18.22 17.75 25 7171 69823 90551428
Arterial haemorrhage 18.08 17.75 7 7189 2516 90618735

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 521.73 17.78 281 7061 101181 42512812
Craniopharyngioma 145.32 17.78 27 7315 239 42613754
Mechanical ventilation complication 97.80 17.78 23 7319 681 42613312
Water intoxication 92.54 17.78 20 7322 400 42613593
Diabetes insipidus 86.14 17.78 30 7312 3683 42610310
Osmotic demyelination syndrome 84.64 17.78 22 7320 990 42613003
Haemothorax 79.62 17.78 31 7311 5205 42608788
Inspiratory capacity decreased 72.80 17.78 25 7317 2942 42611051
Chorioretinopathy 71.22 17.78 21 7321 1510 42612483
Hypernatraemia 69.10 17.78 34 7308 9998 42603995
Hyponatraemic encephalopathy 63.69 17.78 11 7331 61 42613932
Head titubation 63.46 17.78 15 7327 454 42613539
Adverse reaction 58.45 17.78 23 7319 3970 42610023
Face oedema 56.55 17.78 33 7309 13633 42600360
Labelled drug-disease interaction medication error 55.63 17.78 11 7331 139 42613854
Shock haemorrhagic 53.78 17.78 34 7308 16208 42597785
Hypovolaemia 53.60 17.78 30 7312 11455 42602538
Angiopathy 51.84 17.78 23 7319 5354 42608639
Seizure 47.55 17.78 79 7263 120482 42493511
Epistaxis 45.84 17.78 57 7285 66769 42547224
Cogwheel rigidity 43.50 17.78 15 7327 1786 42612207
Emphysema 42.27 17.78 26 7316 11809 42602184
Apnoeic attack 42.08 17.78 11 7331 506 42613487
Hyponatraemic seizure 41.78 17.78 9 7333 177 42613816
Inappropriate antidiuretic hormone secretion 41.18 17.78 29 7313 16512 42597481
Epilepsy 39.26 17.78 34 7308 26137 42587856
Germ cell cancer 39.24 17.78 8 7334 119 42613874
Simple partial seizures 38.91 17.78 10 7332 430 42613563
Polyuria 38.34 17.78 23 7319 9988 42604005
Hypopituitarism 37.10 17.78 15 7327 2776 42611217
Anaphylactic reaction 36.84 17.78 41 7301 42702 42571291
Renal salt-wasting syndrome 34.57 17.78 9 7333 407 42613586
Extrapyramidal disorder 32.35 17.78 25 7317 16387 42597606
Haemorrhage 31.29 17.78 45 7297 60518 42553475
Neoplasm recurrence 30.66 17.78 13 7329 2711 42611282
Tachycardia 30.53 17.78 59 7283 101028 42512965
Sedation complication 29.80 17.78 13 7329 2906 42611087
Insulin-like growth factor increased 29.63 17.78 11 7331 1620 42612373
Anaphylactic shock 28.30 17.78 27 7315 23490 42590503
Insulin-like growth factor decreased 27.97 17.78 7 7335 270 42613723
Duplicate therapy error 27.51 17.78 7 7335 289 42613704
Epiphysiolysis 27.43 17.78 6 7336 127 42613866
Flatulence 26.77 17.78 27 7315 25125 42588868
Pneumothorax 26.40 17.78 26 7316 23517 42590476
Serotonin syndrome 26.15 17.78 27 7315 25818 42588175
Reaction to excipient 26.12 17.78 8 7334 654 42613339
Recalled product administered 25.41 17.78 8 7334 717 42613276
Hyperadrenocorticism 25.18 17.78 6 7336 188 42613805
Pharyngeal haemorrhage 24.59 17.78 8 7334 796 42613197
Polydipsia 24.47 17.78 13 7329 4475 42609518
Perforation 23.79 17.78 7 7335 499 42613494
Adrenocortical insufficiency acute 23.05 17.78 10 7332 2205 42611788
Nephrogenic diabetes insipidus 22.80 17.78 9 7333 1565 42612428
Blood sodium increased 22.43 17.78 11 7331 3207 42610786
Subcutaneous emphysema 22.08 17.78 9 7333 1700 42612293
Urine osmolarity increased 21.84 17.78 5 7337 131 42613862
Hypersensitivity 21.54 17.78 42 7300 72328 42541665
CNS germinoma 20.92 17.78 3 7339 3 42613990
Implant site pruritus 20.92 17.78 3 7339 3 42613990
Compulsive shopping 20.03 17.78 6 7336 455 42613538
Tracheal injury 19.85 17.78 4 7338 56 42613937
Urinary retention 19.82 17.78 30 7312 42184 42571809
Urinary tract infection 19.75 17.78 49 7293 99235 42514758
Anticholinergic syndrome 19.28 17.78 8 7334 1581 42612412
Akathisia 18.61 17.78 15 7327 10436 42603557
Toxic neuropathy 18.52 17.78 6 7336 589 42613404
Hypothalamo-pituitary disorder 18.46 17.78 7 7335 1093 42612900
Pollakiuria 18.38 17.78 21 7321 22484 42591509
Flushing 18.37 17.78 27 7315 37001 42576992

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 1163.53 15.35 542 12102 217111 110359544
Hyponatraemic encephalopathy 217.75 15.35 38 12606 360 110576295
Craniopharyngioma 206.29 15.35 36 12608 341 110576314
Hypernatraemia 190.44 15.35 73 12571 17760 110558895
Water intoxication 178.56 15.35 37 12607 922 110575733
Seizure 155.64 15.35 157 12487 221028 110355627
Diabetes insipidus 152.39 15.35 48 12596 6522 110570133
Hyponatraemic seizure 146.29 15.35 30 12614 709 110575946
Osmotic demyelination syndrome 120.51 15.35 31 12613 2032 110574623
Mechanical ventilation complication 105.09 15.35 23 12621 748 110575907
Renal salt-wasting syndrome 91.09 15.35 21 12623 867 110575788
Polyuria 90.42 15.35 43 12601 17695 110558960
Recalled product administered 88.41 15.35 22 12622 1260 110575395
Haemothorax 86.73 15.35 32 12612 6999 110569656
Inspiratory capacity decreased 86.17 15.35 25 12619 2570 110574085
Pharyngeal haemorrhage 81.48 15.35 21 12623 1386 110575269
Labelled drug-disease interaction medication error 79.19 15.35 16 12628 350 110576305
Cerebral salt-wasting syndrome 76.30 15.35 15 12629 284 110576371
Adrenocortical insufficiency acute 72.95 15.35 25 12619 4415 110572240
Germ cell cancer 68.67 15.35 13 12631 200 110576455
Blood sodium decreased 64.27 15.35 45 12599 38274 110538381
Hypopituitarism 61.69 15.35 22 12622 4368 110572287
Epistaxis 58.02 15.35 73 12571 130299 110446356
Hypovolaemia 54.95 15.35 33 12611 21641 110555014
Angiopathy 53.34 15.35 24 12620 8706 110567949
Nephrogenic diabetes insipidus 53.12 15.35 17 12627 2428 110574227
Shock haemorrhagic 52.82 15.35 35 12609 27212 110549443
Urine output increased 50.94 15.35 17 12627 2769 110573886
Neoplasm recurrence 50.81 15.35 20 12624 5212 110571443
Inappropriate antidiuretic hormone secretion 50.45 15.35 37 12607 33814 110542841
Poor quality product administered 49.53 15.35 19 12625 4622 110572033
Brain injury 49.04 15.35 26 12618 13450 110563205
Face oedema 46.33 15.35 35 12609 33434 110543221
Blood sodium increased 46.32 15.35 19 12625 5504 110571151
Product prescribing error 42.68 15.35 40 12604 51291 110525364
Apnoeic attack 41.62 15.35 11 12633 801 110575854
Drug interaction 40.13 15.35 137 12507 500046 110076609
Emphysema 39.81 15.35 26 12618 19730 110556925
Tonsillar disorder 39.24 15.35 12 12632 1477 110575178
Chorioretinopathy 38.01 15.35 13 12631 2282 110574373
Haemorrhage 35.66 15.35 52 12592 106640 110470015
Simple partial seizures 34.48 15.35 10 12634 1026 110575629
Joint swelling 34.14 15.35 5 12639 442840 110133815
Drug dose omission by device 33.97 15.35 21 12623 14495 110562160
Lethargy 33.31 15.35 47 12597 93529 110483126
Pneumothorax 32.26 15.35 29 12615 35256 110541399
Head titubation 31.82 15.35 10 12634 1347 110575308
Polydipsia 31.31 15.35 16 12628 7672 110568983
Electrolyte imbalance 31.06 15.35 29 12615 36999 110539656
Oesophageal disorder 30.74 15.35 12 12632 3058 110573597
Flushing 30.67 15.35 48 12596 104688 110471967
Urine osmolarity decreased 30.02 15.35 6 12638 124 110576531
Epilepsy 29.45 15.35 46 12598 100163 110476492
Epiphysiolysis 28.42 15.35 6 12638 164 110576491
Drug intolerance 28.26 15.35 6 12638 406506 110170149
Oligohydramnios 27.69 15.35 12 12632 3982 110572673
Duplicate therapy error 27.62 15.35 7 12637 432 110576223
Thoracotomy 27.60 15.35 6 12638 189 110576466
Pain 27.24 15.35 42 12602 954913 109621742
Insulin-like growth factor increased 26.67 15.35 10 12634 2286 110574369
Flatulence 26.09 15.35 31 12613 52118 110524537
Cutaneous lupus erythematosus 25.89 15.35 11 12633 3477 110573178
Puncture site haematoma 25.56 15.35 6 12638 268 110576387
Drug hypersensitivity 25.52 15.35 10 12634 454080 110122575
Hyperadrenocorticism 25.41 15.35 7 12637 596 110576059
Insulin-like growth factor decreased 25.30 15.35 7 12637 606 110576049
Urine osmolarity increased 25.02 15.35 6 12638 294 110576361
Adverse reaction 24.48 15.35 23 12621 29571 110547084
Puncture site haemorrhage 24.07 15.35 7 12637 725 110575930
Rheumatoid arthritis 23.99 15.35 3 12641 299610 110277045
Tachycardia 23.59 15.35 68 12576 226577 110350078
Acromegaly 23.33 15.35 5 12639 147 110576508
Anaphylactic shock 23.13 15.35 29 12615 51517 110525138
Contraindicated product prescribed 23.09 15.35 9 12635 2284 110574371
Hypoosmolar state 23.03 15.35 6 12638 413 110576242
Arthropathy 22.73 15.35 3 12641 287519 110289136
Mood altered 22.42 15.35 19 12625 21356 110555299
Hallucination 22.41 15.35 41 12603 101391 110475264
Abortion induced 22.40 15.35 13 12631 8006 110568649
CNS germinoma 22.15 15.35 3 12641 3 110576652
Cogwheel rigidity 22.06 15.35 10 12634 3688 110572967
Subcutaneous emphysema 22.05 15.35 9 12635 2575 110574080
Urine output decreased 21.53 15.35 18 12626 19858 110556797
Urine sodium increased 21.33 15.35 5 12639 222 110576433
Scleroderma-like reaction 21.31 15.35 5 12639 223 110576432
Hypothalamo-pituitary disorder 21.21 15.35 9 12635 2837 110573818
Pituitary tumour benign 21.21 15.35 9 12635 2838 110573817
Vascular stent thrombosis 20.93 15.35 10 12634 4151 110572504
Astrocytoma 20.66 15.35 5 12639 255 110576400
Arthralgia 20.61 15.35 36 12608 779596 109797059
Urinary retention 20.48 15.35 32 12612 69651 110507004
Reaction to excipient 20.45 15.35 8 12636 2051 110574604
Hepatitis toxic 20.35 15.35 11 12633 5910 110570745
Anaphylactic reaction 20.14 15.35 42 12602 114258 110462397
Blood sodium abnormal 19.76 15.35 7 12637 1363 110575292
Akathisia 19.59 15.35 16 12628 17097 110559558
Extrapyramidal disorder 19.35 15.35 20 12624 28847 110547808
Somnolence 19.19 15.35 76 12568 297373 110279282
Generalised tonic-clonic seizure 18.77 15.35 27 12617 54653 110522002
Headache 18.74 15.35 168 12476 882209 109694446
Off label use 18.74 15.35 257 12387 1499928 109076727
Dyspnoea 18.40 15.35 65 12579 1106807 109469848
Thirst 18.20 15.35 17 12627 21690 110554965
Hepatic enzyme increased 18.13 15.35 7 12637 320885 110255770
Completed suicide 18.07 15.35 3 12641 242378 110334277
Gastrointestinal infection 17.96 15.35 14 12630 13991 110562664
Perforation 17.86 15.35 7 12637 1803 110574852
Haemorrhagic disorder 17.85 15.35 7 12637 1806 110574849
Overdose 17.80 15.35 63 12581 233731 110342924
Melanoderma 17.72 15.35 5 12639 465 110576190
Swelling 17.72 15.35 9 12635 351032 110225623
Infusion related reaction 17.48 15.35 11 12633 381151 110195504
Foetal growth restriction 17.42 15.35 8 12636 3042 110573613
Labelled drug-drug interaction medication error 17.33 15.35 19 12625 29283 110547372
Wound 17.26 15.35 3 12641 234434 110342221
Wheezing 17.26 15.35 4 12640 255226 110321429
Diabetes with hyperosmolarity 17.23 15.35 3 12641 28 110576627
Nasal discomfort 17.21 15.35 10 12634 6171 110570484
Toxic neuropathy 17.20 15.35 6 12638 1117 110575538
Drug ineffective 17.19 15.35 256 12388 1520284 109056371
Metastases to pituitary gland 16.86 15.35 3 12641 32 110576623
Treatment noncompliance 16.75 15.35 30 12614 72960 110503695
Premature delivery 16.64 15.35 19 12625 30613 110546042
Dihydrotestosterone increased 16.11 15.35 3 12641 42 110576613
Tracheal injury 16.01 15.35 4 12640 233 110576422
Glossodynia 16.00 15.35 3 12641 222001 110354654
Aggression 15.77 15.35 26 12618 59184 110517471
Arterial haemorrhage 15.70 15.35 8 12636 3811 110572844
Hyperthermia malignant 15.55 15.35 8 12636 3892 110572763
Urinary tract infection 15.45 15.35 76 12568 326206 110250449
Pollakiuria 15.43 15.35 22 12622 44173 110532482

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H01BA02 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
POSTERIOR PITUITARY LOBE HORMONES
Vasopressin and analogues
FDA CS M0022562 Vasopressins
MeSH PA D003029 Coagulants
MeSH PA D006401 Hematologic Agents
MeSH PA D006490 Hemostatics
MeSH PA D045283 Natriuretic Agents
MeSH PA D050034 Antidiuretic Agents
CHEBI has role CHEBI:33295 diagnostic agent
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35846 renal agent
CHEBI has role CHEBI:59727 vasopressin receptor agonist
FDA EPC N0000175905 Vasopressin Analog
FDA PE N0000175914 Increased Coagulation Factor VIII Activity
FDA PE N0000175915 Increased Coagulation Factor VIII Concentration
FDA EPC N0000175916 Factor VIII Activator
CHEBI has role CHEBI:77715 nasal decongestant

Related Drugs by ATC class:

H01BA Vasopressin and analogues 4 drugs
lypressinornipressinterlipressinvasopressin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Nocturnal enuresis indication 8009008
Hereditary factor VIII deficiency disease indication 28293008 DOID:12134
Polyuria indication 28442001
von Willebrand disorder indication 128105004 DOID:12531
Partial Central Diabetes Insipidus indication
Uremic Bleeding Tendency off-label use
Psychogenic polydipsia contraindication 15945005
Hypertensive disorder contraindication 38341003 DOID:10763
Chronic heart failure contraindication 48447003
Upper respiratory infection contraindication 54150009
Allergic rhinitis contraindication 61582004
Nasal discharge contraindication 64531003
Nasal congestion contraindication 68235000
Water intoxication syndrome contraindication 71785001
Hyponatremia contraindication 89627008
Cystic fibrosis contraindication 190905008 DOID:1485
Impaired renal function disorder contraindication 197663003
Finding of excessive fluid intake contraindication 267026004
Hereditary von Willebrand disease type 2B contraindication 359717002
Disorder of coronary artery contraindication 414024009
Severe Allergic Rhinitis contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.65 acidic
pKa2 12.27 acidic
pKa3 12.64 acidic
pKa4 12.94 acidic
pKa5 13.39 acidic
pKa6 13.43 acidic
pKa7 13.8 acidic
pKa8 10.75 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 DISCN TABLET SUBLINGUAL 11020448 May 21, 2029 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENTS SERUM SODIUM CONCENTRATION
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 DISCN TABLET SUBLINGUAL 11963995 May 21, 2029 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENTS SERUM SODIUM CONCENTRATION
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 DISCN TABLET SUBLINGUAL 10137167 May 21, 2029 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENTS SERUM SODIUM CONCENTRATION
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 DISCN TABLET SUBLINGUAL 11963995 May 21, 2029 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENTS SERUM SODIUM CONCENTRATION
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 DISCN TABLET SUBLINGUAL 9974826 April 13, 2030 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 DISCN TABLET SUBLINGUAL 9974826 April 13, 2030 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENTS SERUM SODIUM CONCENTRATION
0.00083MG/SPRAY NOCTIVA ACERUS PHARMS N201656 March 3, 2017 DISCN SPRAY, METERED NASAL 11419914 June 15, 2030 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INDUCING AN ANTIDIURETIC EFFECT BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF ABOUT 0.05-5 MCG DESMOPRESSIN
0.00083MG/SPRAY NOCTIVA ACERUS PHARMS N201656 March 3, 2017 DISCN SPRAY, METERED NASAL 12090190 June 15, 2030 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF 0.75 MCG OR 1.5 MCG DESMOPRESSIN
0.00166MG/SPRAY NOCTIVA ACERUS PHARMS N201656 March 3, 2017 DISCN SPRAY, METERED NASAL 11419914 June 15, 2030 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INDUCING AN ANTIDIURETIC EFFECT BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF ABOUT 0.05-5 MCG DESMOPRESSIN
0.00166MG/SPRAY NOCTIVA ACERUS PHARMS N201656 March 3, 2017 DISCN SPRAY, METERED NASAL 12090190 June 15, 2030 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF 0.75 MCG OR 1.5 MCG DESMOPRESSIN
0.05MG/ML DESMODA ETON N219873 Feb. 25, 2026 RX SOLUTION ORAL 12343372 April 3, 2044 MANAGEMENT OF CENTRAL DIABETES INSIPIDUS AS ANTIDIURETIC REPLACEMENT THERAPY FOR ADULTS AND PEDIATRIC PATIENTS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Vasopressin V2 receptor GPCR AGONIST Ki 8.30 CHEMBL SCIENTIFIC LITERATURE
Vasopressin V1b receptor GPCR Ki 9.43 CHEMBL
Oxytocin receptor GPCR AGONIST Ki 7.60 IUPHAR
Vasopressin V1a receptor GPCR Ki 8.42 CHEMBL
Oxytocin receptor GPCR Ki 9.01 CHEMBL
Vasopressin V1a receptor GPCR Ki 7.97 CHEMBL
Vasopressin V1b receptor GPCR Ki 9.70 CHEMBL
Vasopressin V2 receptor GPCR Ki 9.10 CHEMBL

External reference:

IDSource
4019709 VUID
N0000170340 NUI
D00291 KEGG_DRUG
62357-86-2 SECONDARY_CAS_RN
203658 RXNORM
4018750 VANDF
4019709 VANDF
C0011701 UMLSCUI
CHEBI:4450 CHEBI
CHEMBL1429 ChEMBL_ID
CHEMBL1200556 ChEMBL_ID
DB00035 DRUGBANK_ID
2182 IUPHAR_LIGAND_ID
3799 INN_ID
ENR1LLB0FP UNII
5311065 PUBCHEM_CID
1069 MMSL
4548 MMSL
48087 MMSL
772 MMSL
d00583 MMSL
002125 NDDF
004784 NDDF
126189002 SNOMEDCT_US
126190006 SNOMEDCT_US
73454001 SNOMEDCT_US
D003894 MESH_DESCRIPTOR_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 10702-169 TABLET 0.10 mg ORAL ANDA 11 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 10702-170 TABLET 0.20 mg ORAL ANDA 11 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 23155-489 TABLET 0.10 mg ORAL ANDA 20 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 23155-490 TABLET 0.20 mg ORAL ANDA 20 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 24208-342 SOLUTION 0.10 mg NASAL ANDA 27 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 24208-342 SOLUTION 0.10 mg NASAL ANDA 27 sections
desmopressin acetate HUMAN PRESCRIPTION DRUG LABEL 1 25021-460 INJECTION, SOLUTION 4 ug INTRAVENOUS ANDA 27 sections
desmopressin acetate HUMAN PRESCRIPTION DRUG LABEL 1 25021-461 INJECTION, SOLUTION 40 ug INTRAVENOUS ANDA 27 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 39822-6200 INJECTION, SOLUTION 4 ug INTRAVENOUS ANDA 27 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 39822-6250 INJECTION, SOLUTION 4 ug SUBCUTANEOUS ANDA 27 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 43598-053 INJECTION, SOLUTION 4 ug INTRAVENOUS ANDA 25 sections
DESMOPRESSIN ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 43598-931 INJECTION 4 ug SUBCUTANEOUS ANDA 13 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 51655-461 TABLET 0.20 mg ORAL ANDA 11 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 54868-1129 TABLET 0.20 mg ORAL ANDA 11 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 54868-5602 SOLUTION 0.10 mg NASAL ANDA 21 sections
DDAVP HUMAN PRESCRIPTION DRUG LABEL 1 55566-2200 INJECTION 4 ug INTRAVENOUS NDA 27 sections
DDAVP HUMAN PRESCRIPTION DRUG LABEL 1 55566-2300 INJECTION 4 ug INTRAVENOUS NDA 27 sections
DDAVP HUMAN PRESCRIPTION DRUG LABEL 1 55566-2600 TABLET 0.10 mg ORAL NDA 21 sections
DDAVP HUMAN PRESCRIPTION DRUG LABEL 1 55566-2700 TABLET 0.20 mg ORAL NDA 21 sections
Stimate HUMAN PRESCRIPTION DRUG LABEL 1 55566-3000 SPRAY 1.50 mg NASAL NDA 27 sections
Desmopressin Acetate Human Prescription Drug Label 1 59651-249 TABLET 0.10 mg ORAL ANDA 20 sections
Desmopressin Acetate Human Prescription Drug Label 1 59651-250 TABLET 0.20 mg ORAL ANDA 20 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 60505-0257 TABLET 0.10 mg ORAL ANDA 20 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 60505-0258 TABLET 0.20 mg ORAL ANDA 20 sections
DESMOPRESSIN ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 60505-0815 SPRAY 10 ug NASAL ANDA 25 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 60687-721 TABLET 0.10 mg ORAL ANDA 20 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 60687-721 TABLET 0.10 mg ORAL ANDA 20 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 60687-732 TABLET 0.20 mg ORAL ANDA 20 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 60687-732 TABLET 0.20 mg ORAL ANDA 20 sections
Desmopressin Acetate Human Prescription Drug Label 1 62756-161 SOLUTION 0.10 mg NASAL ANDA 22 sections